Suzanne A Arinsburg, DO

Insurance Information

Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).

Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.

Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.

Publications

Scopus h-index:12

Article:19

Review Article:4

Letter:1

Chapter:2

Recent Artifacts

• Hospitalized patients with HIV and COVID-19 receiving convalescent plasma: A case series
• Food for thought: Eating before saliva collection and interference with SARS-CoV-2 detection
• The utility and complications of plasma administration in cirrhotic patients undergoing minimally invasive procedures
• Use of an in-house trypsin-based method to resolve the interference of daratumumab
• Mycophenolate Mofetil and Plasmapheresis: A Treatment Option for Severe Insulin Resistance caused by Insulin Antibodies
• Role of Immunoglobulin M and A Antibodies in the Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2
• Neutralizing Antibody Responses in COVID-19 Convalescent Sera
• Transfusion reactions associated with COVID-19 convalescent plasma therapy for SARS-CoV-2
• Quantifying absolute neutralization titers against sars-cov-2 by a standardized virus neutralization assay allows for cross-cohort comparisons of covid-19 sera
• A high-throughput assay for circulating antibodies directed against the s protein of severe acute respiratory syndrome coronavirus 2

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Arinsburg during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.